AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.48
-0.19 (-3.35%)
Jul 24, 2026, 1:23 PM EDT - Market open
AbCellera Biologics Market Cap
AbCellera Biologics has a market cap or net worth of $1.67 billion as of July 24, 2026. Its market cap has increased by 12.35% in one year.
Market Cap
1.67B
Enterprise Value
1.30B
1-Year Change
12.35%
Ranking
Category
Stock Price
$5.48
ChartMarket Cap Chart
Since the IPO on December 11, 2020, AbCellera Biologics's market cap has decreased from $15.66B to $1.67B, a decrease of -89.32%. That is a compound annual growth rate of -32.83%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 1.67B | 63.47% |
| Dec 31, 2025 | 1.02B | 18.29% |
| Dec 31, 2024 | 865.42M | -47.77% |
| Dec 29, 2023 | 1.66B | -42.83% |
| Dec 30, 2022 | 2.90B | -28.02% |
| Dec 31, 2021 | 4.03B | -62.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 11, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bicara Therapeutics | 1.84B |
| Maravai LifeSciences Holdings | 1.83B |
| Tyra Biosciences | 1.82B |
| Taysha Gene Therapies | 1.81B |
| Immunocore Holdings | 1.81B |
| Stoke Therapeutics | 1.80B |
| Generate Biomedicines | 1.78B |
| Ascentage Pharma Group International | 1.76B |